1. Home
  2. PGR vs VRTX Comparison

PGR vs VRTX Comparison

Compare PGR & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Progressive Corporation (The)

PGR

Progressive Corporation (The)

HOLD

Current Price

$195.59

Market Cap

120.2B

Sector

Finance

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$436.40

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGR
VRTX
Founded
1937
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
EDP Services
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
120.2B
115.7B
IPO Year
2008
2006

Fundamental Metrics

Financial Performance
Metric
PGR
VRTX
Price
$195.59
$436.40
Analyst Decision
Buy
Buy
Analyst Count
14
29
Target Price
$237.77
$539.08
AVG Volume (30 Days)
2.6M
1.3M
Earning Date
04-15-2026
05-04-2026
Dividend Yield
7.12%
N/A
EPS Growth
33.54
836.54
EPS
19.23
15.32
Revenue
$87,671,000,000.00
$2,488,652,000.00
Revenue This Year
$3.35
$10.81
Revenue Next Year
$8.05
$10.26
P/E Ratio
$10.15
$28.64
Revenue Growth
16.32
46.20
52 Week Low
$192.02
$362.50
52 Week High
$289.78
$510.77

Technical Indicators

Market Signals
Indicator
PGR
VRTX
Relative Strength Index (RSI) 38.38 39.13
Support Level N/A $431.51
Resistance Level $215.87 $442.22
Average True Range (ATR) 4.69 10.44
MACD -0.89 -1.92
Stochastic Oscillator 22.67 14.98

Price Performance

Historical Comparison
PGR
VRTX

About PGR Progressive Corporation (The)

Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 27 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: